## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ss-31-glp-1`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ss-31-glp-1/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-glp-1/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-glp-1/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ss-31-glp-1/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-glp-1/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ss-31-glp-1/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ss-31-glp-1` v2 · content_hash `e83414d2d078ec0f…` · thread_head genesis · 23 DIVs
- **thesis (c1):** SS-31 binds cardiolipin in the inner mitochondrial membrane and is associated with improved electron transport efficiency in preclinical models.
  - c2 [human/active] A randomized placebo-controlled trial in primary mitochondrial myopathy patients showed dose-dependent improvement in 6-minute walk distance after 5 days of IV 
  - c4 [human/active] No published human trials examine concurrent SS-31 and GLP-1 agonist use.
  - c5 [human/active] FDA granted accelerated approval to elamipretide (SS-31) for Barth syndrome in 2025 based on TAZPOWER trial data.
  - c3 [mechanistic/active] GLP-1 agonists produce weight loss that mechanically unloads the spine and joints by approximately 4 lb compressive force per pound lost.
  - c6 [anecdotal/active] Reddit users report subjective energy or fatigue changes when using SS-31 alongside tirzepatide; reports are anecdotal and mixed.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ss-31-glp-1/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ss-31-glp-1/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ss-31-glp-1`
- **title:** SS-31 (Elamipretide) Mitochondrial Targeting with GLP-1 Agonists: Evidence Layers
- **url:** https://miscsubjects.com/a/ss-31-glp-1
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:03.325Z
- **tags:** peptide, matrix

## Body

## What's breaking down

Mitochondrial energy production can decline with age, metabolic stress, or rapid body composition changes. GLP-1 agonists drive weight loss through appetite reduction and slower gastric emptying. This often produces 1–2+ lb weekly loss, which can include lean mass if protein intake and resistance training lag. Each pound of body weight lost removes roughly 4 lb of compressive force from the spine and joints during daily movement, but the metabolic shift may also increase cellular stress on mitochondria in muscle and other tissues.

SS-31 (elamipretide) is studied for its ability to bind cardiolipin in the inner mitochondrial membrane. This interaction is discussed in preclinical work as supporting electron transport chain efficiency and lowering reactive oxygen species. The article focuses on whether this mitochondrial layer interacts with the metabolic changes seen during GLP-1 use.

## Why SS-31 (Elamipretide) might help you

If mitochondrial bioenergetics form part of your situation while using GLP-1 agonists, SS-31 is examined because it targets repair at the mitochondrial membrane rather than symptom masking.

1. GLP-1 driven weight loss alters energy demand and substrate use.
2. Mitochondria in muscle and other tissues may experience increased oxidative load during this transition.
3. SS-31 concentrates in the inner mitochondrial membrane and associates with cardiolipin.
4. Preclinical models show this association correlates with improved ATP production and reduced electron leak.
5. Therefore, if mitochondrial efficiency is a limiting factor for you during GLP-1 therapy, the peptide is studied for direct membrane stabilization rather than downstream metabolic signaling.

## Why GLP-1 agonists (class) matters for you

GLP-1 agonists primarily support metabolism by enhancing insulin secretion, suppressing glucagon, and slowing gastric emptying. This produces sustained caloric deficit and weight reduction. The weight loss itself lowers mechanical load on the musculoskeletal system—approximately 4 lb of lumbar compressive force per pound lost. However, rapid loss can trade off against lean mass preservation if resistance training and protein are insufficient. The drug class does not directly address mitochondrial membrane integrity; any mitochondrial benefit would be indirect through reduced adiposity and improved glycemic control.

## How these fit together

SS-31 addresses the mitochondrial membrane layer. GLP-1 agonists address systemic energy balance and mechanical unloading. In a single-compound focus on SS-31, the two are considered together because mitochondrial repair pathways may complement the metabolic unloading that occurs with GLP-1 use, without overlapping mechanisms.

## What the evidence actually shows

Human trial data for SS-31 exists in primary mitochondrial myopathy and heart failure populations. One randomized, placebo-controlled trial in adults with primary mitochondrial myopathy reported a dose-dependent increase in 6-minute walk test distance after 5 days of intravenous dosing (Class I evidence for short-term exercise performance). A phase 3 trial (MMPOWER-3) showed mixed genotype-specific results. In heart failure, a 28-day subcutaneous study found the compound well tolerated but did not meet primary efficacy endpoints in all measures.

Preclinical studies (rodent and cell models) consistently demonstrate cardiolipin binding, improved mitochondrial respiration, and reduced ROS. No published human trials examine SS-31 combined with GLP-1 agonists. Evidence inventory: multiple human trials (phase 2/3) for mitochondrial disease indications; dozens of animal studies on mitochondrial function; limited anecdotal reports of concurrent use with GLP-1 compounds on forums.

## What scientists say

Researchers describe SS-31 as selectively localizing to mitochondria and stabilizing cardiolipin to support electron transport chain supercomplexes. Clinical trial summaries note good short-term tolerability with injection-site reactions as the main observation. Long-term human data beyond 28–168 weeks in specific rare-disease cohorts remain limited. No peer-reviewed statements address direct synergy with GLP-1 agonists.

## What people say on Reddit

Forum users report trying SS-31 alongside tirzepatide or semaglutide for perceived energy support during weight loss. Some describe subjective improvements in fatigue or skin appearance when stacking with other compounds; others note initial fatigue or GI adjustment symptoms that later subsided. Posts emphasize that SS-31 remains investigational outside approved rare-disease indications and stress sourcing and monitoring concerns.

## What people say on X

Public posts on X largely mirror forum discussions: users reference ongoing trials, share interest in mitochondrial peptides during GLP-1 therapy, and note the 2025 FDA approval for Barth syndrome. Anecdotal tone dominates; quantitative outcome reports are absent.

## What we do not know

No human data exist on combined SS-31 and GLP-1 agonist protocols. Long-term safety beyond approved indications is not established. Effects on muscle preservation during GLP-1 weight loss remain untested. Optimal sequencing or duration for any potential mitochondrial support layer is unknown.

## Safety and limits

In published trials, SS-31 was generally well tolerated. Most common observations were mild injection-site reactions (erythema, pruritus). Occasional reports mention headache or dizziness. No serious adverse events were linked to the peptide in the reviewed studies. Because human combination data with GLP-1 agonists are absent, any interaction profile is unknown. The compound holds FDA approval only for specific rare mitochondrial disease; use outside those indications is off-label and investigational.

## Claims (6)

- **c4** [human w=0.8] No published human trials examine concurrent SS-31 and GLP-1 agonist use.
  - who_claims: grok/grok-4.3
- **c1** [preclinical w=0.5] SS-31 binds cardiolipin in the inner mitochondrial membrane and is associated with improved electron transport efficiency in preclinical models.
  - who_claims: grok/grok-4.3
  - sources: s14
- **c3** [mechanistic w=0.3] GLP-1 agonists produce weight loss that mechanically unloads the spine and joints by approximately 4 lb compressive force per pound lost.
  - who_claims: grok/grok-4.3
- **c2** [human w=0.8] A randomized placebo-controlled trial in primary mitochondrial myopathy patients showed dose-dependent improvement in 6-minute walk distance after 5 days of IV SS-31 (Class I evidence).
  - who_claims: grok/grok-4.3
  - sources: s5
- **c5** [human w=0.8] FDA granted accelerated approval to elamipretide (SS-31) for Barth syndrome in 2025 based on TAZPOWER trial data.
  - who_claims: grok/grok-4.3
  - sources: s19
- **c6** [anecdotal w=0.3] Reddit users report subjective energy or fatigue changes when using SS-31 alongside tirzepatide; reports are anecdotal and mixed.
  - who_claims: grok/grok-4.3
  - sources: s10

## Voxel graph (6 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/ss-31-glp-1/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (4)
- chain valid: yes · head: `a25b289ab7727729`

### s5 · pubmed · ok
- title: Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
- url: https://www.neurology.org/doi/10.1212/WNL.0000000000005255
- summary: Class I evidence for short-term exercise improvement in PMM patients.
- quote: Participants who received the highest dose of elamipretide walked a mean of 64.5 m farther at day 5 compared to a change of 20.4 m in the placebo group (p = 0.053).
- claim_ids: c2
- hash: `2315a846a52abfcf`

### s10 · reddit · ok
- title: Anyone here taking other peptides along with tirzepatide?
- url: https://www.reddit.com/r/compoundedtirzepatide/comments/1scbh7n/anyone_here_taking_other_peptides_along_with/
- summary: Anecdotal report of SS-31 with tirzepatide.
- quote: I do feel like I get a little energy boost from the 5Amino/ ss-31...
- claim_ids: c6
- hash: `a25b289ab7727729`

### s14 · pubmed · ok
- title: Mitochondrial protein interaction landscape of SS-31
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC7334473/
- summary: Identifies SS-31 interactors linked to ATP production and 2-oxoglutarate metabolism.
- quote: The synthetic tetrapeptide, elamipretide (SS-31), improves mitochondrial function, but mechanistic details of its pharmacological effects are unknown.
- claim_ids: c1
- hash: `942b2c42e49f0f64`

### s19 · news · ok
- title: FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31
- url: https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/
- summary: Reports 2025 FDA approval for Barth syndrome.
- quote: The recent FDA approval of elamipretide is for the treatment of a rare disease...
- claim_ids: c5
- hash: `8ad2641afe4c0f0c`

## Provenance (2 model passes)
- chain valid: yes · head: `5339d8ba65011c31`

- write · grok/grok-4.3 · 2026-06-29T23:55 · hash `b87817cb8e50`
- voxel_divide · owner · 2026-07-17T02:42 · hash `5339d8ba6501`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ss-31-glp-1/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ss-31-glp-1/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ss-31-glp-1","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ss-31-glp-1|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ss-31-glp-1|tier|assertion`
- **iMessage ask:** `ss-31-glp-1|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ss-31-glp-1`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-glp-1/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-glp-1/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*